TY - JOUR
T1 - Pharmacist-provided rapid HIV testing in two community pharmacies
AU - Darin, Kristin M.
AU - Klepser, Michael E.
AU - Klepser, Donald E.
AU - Klepser, Stephanie A.
AU - Reeves, Andrew
AU - Young, Maria
AU - Scarsi, Kimberly K.
N1 - Funding Information:
Disclosure: Drs. Donald G. Klepser, Stephanie A. Klepser, and Michael E. Klepser have received grants from the National Association of Chain Drug Stores Foundation and Gilead Sciences, Inc. for projects related to rapid diagnostic testing and are co-creators of the point-of-care testing certificate program administered by the Michigan Pharmacists Association. The authors declare no other relevant conflicts of interest or financial relationships.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objective: To evaluate the acceptability and feasibility of pharmacist-provided rapid testing for human immunodeficiency virus (HIV) infection in community pharmacies. Practice description: A pharmacist-provided HIV testing model - including rapid HIV testing, counseling, and linkage to confirmatory HIV testing services - was developed and implemented. Setting: Two independent pharmacies located in Michigan cities of different size and with different prevalence of HIV infection. Main outcome measures: Number of HIV tests performed, time required for HIV testing services, description of participants who received an HIV test, and pharmacist and participant perception of the HIV testing experience. Results: From October 2011 to March 2013, pharmacists provided HIV tests to 69 participants. One (1.5%) participant had a reactive HIV test and was immediately referred to an appropriate health care provider for confirmatory testing. HIV testing services required a median time of 30 (range, 20-90) minutes. Participants had a median age of 23 (range, 18-61) years and were diverse by gender (59.4% women) and race (46.4% black; 39.1% white). This was the first HIV test for 42% of participants, many of whom reported high-risk behaviors in the prior 6 months. Participants and pharmacists reported favorable perceptions of the HIV testing experience. Conclusion: This project demonstrates the acceptability and feasibility of pharmacist-provided rapid HIV testing in two community pharmacies with distinct characteristics. Further development of HIV testing services in this practice setting is warranted.
AB - Objective: To evaluate the acceptability and feasibility of pharmacist-provided rapid testing for human immunodeficiency virus (HIV) infection in community pharmacies. Practice description: A pharmacist-provided HIV testing model - including rapid HIV testing, counseling, and linkage to confirmatory HIV testing services - was developed and implemented. Setting: Two independent pharmacies located in Michigan cities of different size and with different prevalence of HIV infection. Main outcome measures: Number of HIV tests performed, time required for HIV testing services, description of participants who received an HIV test, and pharmacist and participant perception of the HIV testing experience. Results: From October 2011 to March 2013, pharmacists provided HIV tests to 69 participants. One (1.5%) participant had a reactive HIV test and was immediately referred to an appropriate health care provider for confirmatory testing. HIV testing services required a median time of 30 (range, 20-90) minutes. Participants had a median age of 23 (range, 18-61) years and were diverse by gender (59.4% women) and race (46.4% black; 39.1% white). This was the first HIV test for 42% of participants, many of whom reported high-risk behaviors in the prior 6 months. Participants and pharmacists reported favorable perceptions of the HIV testing experience. Conclusion: This project demonstrates the acceptability and feasibility of pharmacist-provided rapid HIV testing in two community pharmacies with distinct characteristics. Further development of HIV testing services in this practice setting is warranted.
UR - http://www.scopus.com/inward/record.url?scp=84920970007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920970007&partnerID=8YFLogxK
U2 - 10.1331/JAPhA.2015.14070
DO - 10.1331/JAPhA.2015.14070
M3 - Article
C2 - 25415222
AN - SCOPUS:84920970007
SN - 1544-3191
VL - 55
SP - 81
EP - 88
JO - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
JF - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
IS - 1
ER -